TapewireFind a company

person · Reporting owner

Lippoldt Darin

Disclosed activity across 1 company

Tapewire entity
30876
SEC CIK
0001504783

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655Chief Legal OfficerSeptember 11, 2026September 15, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

NEUROCRINE BIOSCIENCES INC

Report date September 11, 2026 · Filed September 15, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect56,793 Ending reported balance After 2026-09-11 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-09-11 · Grant · Acquired 4,483 · Balance 59,212

F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

Row 2 · 2026-09-11 · Tax withholding · Disposed 2,419 · Balance 56,793

F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 31, 2025 Filed Feb 4, 2025 22:49 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 2,373 $0.00 $0.00
Disclosure

SEC source: 0000914475-25-000026 · wk-form4_1738709367.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,113

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 01, 2024 Filed Aug 5, 2024 21:18 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 2,996 $0.00 Strike: $79.02 $0.00
Disclosure

SEC source: 0000914475-24-000185 · wk-form4_1722892706.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,372

Underlying: Common Stock · 2,996 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
August 01, 2024 Filed Aug 5, 2024 21:18 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 2,996 $154.01 $461,422.95
Disclosure

SEC source: 0000914475-24-000185 · wk-form4_1722892706.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,740

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.07 to $154.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 01, 2024 Filed Aug 5, 2024 21:18 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 2,996 $79.02 $236,743.92
Disclosure

SEC source: 0000914475-24-000185 · wk-form4_1722892706.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,736

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 16, 2024 Filed Jul 18, 2024 20:41 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 7,004 $0.00 Strike: $79.02 $0.00
Disclosure

SEC source: 0000914475-24-000168 · wk-form4_1721335256.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,368

Underlying: Common Stock · 7,004 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
July 16, 2024 Filed Jul 18, 2024 20:41 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 7,004 $150.00 $1,050,590.19
Disclosure

SEC source: 0000914475-24-000168 · wk-form4_1721335256.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,740

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $149.80 to $150.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
July 16, 2024 Filed Jul 18, 2024 20:41 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 7,004 $79.02 $553,456.08
Disclosure

SEC source: 0000914475-24-000168 · wk-form4_1721335256.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,744

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:45 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantRestricted Stock Unit · Derivative 8,070 $0.00 $0.00
Disclosure

SEC source: 0000914475-24-000074 · wk-form4_1708037139.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,070

Underlying: Common Stock · 8,070 shares

Expires not disclosed

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:45 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantStock Option · Derivative 40,552 $0.00 Strike: $133.84 $0.00
Disclosure

SEC source: 0000914475-24-000074 · wk-form4_1708037139.xml · derivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,552

Underlying: Common Stock · 40,552 shares

Expires 2034-02-13

F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:45 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 1,098 $132.99 $146,028.40
Disclosure

SEC source: 0000914475-24-000074 · wk-form4_1708037139.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,740

F1 · kind: Sale of 1,098 shares of common stock issued upon vesting of 2,083 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (985) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 00:25 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 911 $134.24 $122,288.90
Disclosure

SEC source: 0000914475-24-000048 · wk-form4_1707438316.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,755

F3 · kind: Sale of 911 shares of common stock issued upon vesting of 1,727 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (816) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 06, 2024 Filed Feb 9, 2024 00:25 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 1,041 $142.17 $147,995.12
Disclosure

SEC source: 0000914475-24-000048 · wk-form4_1707438316.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,939

F1 · kind: Sale of 1,041 shares of common stock issued upon vesting of 1,975 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (934) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.04 to $143.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 31, 2024 Filed Feb 3, 2024 00:24 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 1,250 $140.65 $175,809.75
Disclosure

SEC source: 0000914475-24-000029 · wk-form4_1706919870.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,005

F1 · kind: Sale of 1,250 shares of common stock issued upon vesting of 2,373 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,123) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.75 to $142.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 22, 2024 Filed Jan 24, 2024 22:47 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 10,000 $79.02 Strike: $79.02 $790,200.00
Disclosure

SEC source: 0000914475-24-000011 · wk-form4_1706136421.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,372

Underlying: Common Stock · 10,000 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
January 22, 2024 Filed Jan 24, 2024 22:47 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 10,000 $139.86 $1,398,553.00
Disclosure

SEC source: 0000914475-24-000011 · wk-form4_1706136421.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,882

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.80 to $139.99. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 22, 2024 Filed Jan 24, 2024 22:47 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 10,000 $79.02 $790,200.00
Disclosure

SEC source: 0000914475-24-000011 · wk-form4_1706136421.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,882

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 06, 2023 Filed Dec 8, 2023 23:23 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 20,830 $43.24 Strike: $43.24 $900,689.20
Disclosure

SEC source: 0000914475-23-000082 · wk-form4_1702077782.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,376

Underlying: Common Stock · 20,830 shares

Expires 2027-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option granted February 06, 2017 and vested monthly over four years.

Read SEC document
December 06, 2023 Filed Dec 8, 2023 23:23 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 20,830 $119.86 $2,496,648.39
Disclosure

SEC source: 0000914475-23-000082 · wk-form4_1702077782.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,882

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $119.81 to $120.0350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
December 06, 2023 Filed Dec 8, 2023 23:23 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 20,830 $43.24 $900,689.20
Disclosure

SEC source: 0000914475-23-000082 · wk-form4_1702077782.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,712

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 27, 2023 Filed Nov 29, 2023 21:36 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 10,919 $112.27 $1,225,911.07
Disclosure

SEC source: 0001209191-23-056907 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,882

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.21 to $113.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 30, 2023 Filed Sep 1, 2023 20:31 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GiftCommon Stock 190 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-047966 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,801

Read SEC document
August 21, 2023 Filed Aug 24, 2023 00:09 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 2,132 $107.39 $228,951.22
Disclosure

SEC source: 0001209191-23-047138 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,991

F1 · kind: Sale of 2,132 shares of common stock issued upon vesting of 4,050 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,918) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.05 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 13, 2023 Filed Feb 16, 2023 00:13 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantRestricted Stock Unit · Derivative 8,332 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-009887 · doc4.xml · derivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,332

Underlying: Common Stock · 8,332 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027.

F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027.

Read SEC document
February 13, 2023 Filed Feb 16, 2023 00:13 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantStock Option · Derivative 51,782 $0.00 Strike: $103.52 $0.00
Disclosure

SEC source: 0001209191-23-009887 · doc4.xml · derivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,782

Underlying: Common Stock · 51,782 shares

Expires 2033-02-13

F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 08, 2023 Filed Feb 9, 2023 00:32 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 911 $104.08 $94,814.97
Disclosure

SEC source: 0001209191-23-007913 · doc4.xml · nonDerivative · entry 4

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,973

F8 · kind: Sale of 911 shares of common stock issued upon vesting of 1,727 restricted stock units on February 8, 2023 to cover payroll and withholding taxes, with the balance of the shares (816) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F9 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.58 to $105.72. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 07, 2023 Filed Feb 9, 2023 00:32 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 12,801 $102.42 $1,311,066.90
Disclosure

SEC source: 0001209191-23-007913 · doc4.xml · nonDerivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,157

F5 · kind: Sale of 12,801 shares of common stock issued upon vesting of 24,298 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (11,497) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F6 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023.

F7 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $99.93 to $103.90. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 07, 2023 Filed Feb 9, 2023 00:32 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 1,522 $102.24 $155,613.39
Disclosure

SEC source: 0001209191-23-007913 · doc4.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,660

F3 · kind: Sale of 1,522 shares of common stock issued upon vesting of 2,892 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,370) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.57 to $103.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 06, 2023 Filed Feb 9, 2023 00:32 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 1,041 $105.80 $110,141.44
Disclosure

SEC source: 0001209191-23-007913 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,290

F1 · kind: Sale of 1,041 shares of common stock issued upon vesting of 1,974 restricted stock units on February 6, 2023 to cover payroll and withholding taxes, with the balance of the shares (933) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.65 to $108.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 22:21 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 1,250 $109.97 $137,464.00
Disclosure

SEC source: 0001209191-23-006277 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,357

F1 · kind: Sale of 1,250 shares of common stock issued upon vesting of 2,373 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,123) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
November 08, 2022 Filed Nov 10, 2022 22:48 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 5,082 $43.24 Strike: $43.24 $219,745.68
Disclosure

SEC source: 0001209191-22-056436 · doc4.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,206

Underlying: Common Stock · 5,082 shares

Expires 2027-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option granted February 06, 2017 and vested monthly over four years.

Read SEC document
November 08, 2022 Filed Nov 10, 2022 22:48 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 5,082 $125.04 $635,441.59
Disclosure

SEC source: 0001209191-22-056436 · doc4.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,234

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
November 08, 2022 Filed Nov 10, 2022 22:48 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 5,082 $43.24 $219,745.68
Disclosure

SEC source: 0001209191-22-056436 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,316

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 03, 2022 Filed Nov 4, 2022 21:51 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 4,518 $43.24 Strike: $43.24 $195,358.32
Disclosure

SEC source: 0001209191-22-055837 · doc4.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,288

Underlying: Common Stock · 4,518 shares

Expires 2027-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option granted February 06, 2017 and vested monthly over four years.

Read SEC document
November 03, 2022 Filed Nov 4, 2022 21:51 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 4,518 $125.02 $564,851.20
Disclosure

SEC source: 0001209191-22-055837 · doc4.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,234

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.17. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
November 03, 2022 Filed Nov 4, 2022 21:51 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 4,518 $43.24 $195,358.32
Disclosure

SEC source: 0001209191-22-055837 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,752

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 02, 2022 Filed Nov 2, 2022 22:33 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 400 $43.24 Strike: $43.24 $17,296.00
Disclosure

SEC source: 0001209191-22-055391 · doc4.xml · derivative · entry 6

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,806

Underlying: Common Stock · 400 shares

Expires 2027-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option granted February 06, 2017 and vested monthly over four years.

Read SEC document
November 02, 2022 Filed Nov 2, 2022 22:33 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 400 $125.00 $50,000.00
Disclosure

SEC source: 0001209191-22-055391 · doc4.xml · nonDerivative · entry 4

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,234

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
November 02, 2022 Filed Nov 2, 2022 22:33 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 400 $43.24 $17,296.00
Disclosure

SEC source: 0001209191-22-055391 · doc4.xml · nonDerivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,634

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 01, 2022 Filed Nov 2, 2022 22:33 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 10,000 $43.24 Strike: $43.24 $432,400.00
Disclosure

SEC source: 0001209191-22-055391 · doc4.xml · derivative · entry 5

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,206

Underlying: Common Stock · 10,000 shares

Expires 2027-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option granted February 06, 2017 and vested monthly over four years.

Read SEC document
November 01, 2022 Filed Nov 2, 2022 22:33 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 10,000 $120.09 $1,200,899.00
Disclosure

SEC source: 0001209191-22-055391 · doc4.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,234

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
November 01, 2022 Filed Nov 2, 2022 22:33 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 10,000 $43.24 $432,400.00
Disclosure

SEC source: 0001209191-22-055391 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 27, 2022 Filed Oct 28, 2022 21:45 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 4,923 $43.24 Strike: $43.24 $212,870.52
Disclosure

SEC source: 0001209191-22-054840 · doc4.xml · derivative · entry 6

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,206

Underlying: Common Stock · 4,923 shares

Expires 2027-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option granted February 06, 2017 and vested monthly over four years.

Read SEC document
October 27, 2022 Filed Oct 28, 2022 21:45 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 4,923 $115.04 $566,331.58
Disclosure

SEC source: 0001209191-22-054840 · doc4.xml · nonDerivative · entry 4

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,234

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.00 to $115.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 27, 2022 Filed Oct 28, 2022 21:45 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 4,923 $43.24 $212,870.52
Disclosure

SEC source: 0001209191-22-054840 · doc4.xml · nonDerivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,157

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 26, 2022 Filed Oct 28, 2022 21:45 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 5,077 $43.24 Strike: $43.24 $219,529.48
Disclosure

SEC source: 0001209191-22-054840 · doc4.xml · derivative · entry 5

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,129

Underlying: Common Stock · 5,077 shares

Expires 2027-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option granted February 06, 2017 and vested monthly over four years.

Read SEC document
October 26, 2022 Filed Oct 28, 2022 21:45 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 5,077 $115.02 $583,965.68
Disclosure

SEC source: 0001209191-22-054840 · doc4.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,234

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.00 to $115.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 26, 2022 Filed Oct 28, 2022 21:45 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 5,077 $43.24 $219,529.48
Disclosure

SEC source: 0001209191-22-054840 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,311

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 04, 2022 Filed Oct 5, 2022 22:33 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 10,000 $43.24 Strike: $43.24 $432,400.00
Disclosure

SEC source: 0001209191-22-052885 · doc4.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,206

Underlying: Common Stock · 10,000 shares

Expires 2027-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option granted February 06, 2017 and vested monthly over four years.

Read SEC document
October 04, 2022 Filed Oct 5, 2022 22:33 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 10,000 $111.04 $1,110,446.00
Disclosure

SEC source: 0001209191-22-052885 · doc4.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,234

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $111.99. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 04, 2022 Filed Oct 5, 2022 22:33 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 10,000 $43.24 $432,400.00
Disclosure

SEC source: 0001209191-22-052885 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.